Valencia, Alfredo M.
Sankar, Akshay
van der Sluijs, Pleuntje J. http://orcid.org/0000-0002-1174-2806
Satterstrom, F. Kyle http://orcid.org/0000-0001-6187-7680
Fu, Jack
Talkowski, Michael E. http://orcid.org/0000-0003-2889-0992
Vergano, Samantha A. Schrier http://orcid.org/0000-0001-9194-0644
Santen, Gijs W. E. http://orcid.org/0000-0003-1959-3267
Kadoch, Cigall http://orcid.org/0000-0002-4058-5985
Funding for this research was provided by:
Howard Hughes Medical Institute (Gilliam Fellowship (AMV))
Article History
Received: 4 October 2022
Accepted: 20 June 2023
First Online: 27 July 2023
Competing interests
: C.K. is the scientific founder, scientific advisor to the Board of Directors, scientific advisory board member, shareholder and consultant for Foghorn Therapeutics. C.K. is also a member of the scientific advisory board and is a shareholder of Nested Therapeutics, Nereid Therapeutics and Accent Therapeutics, serves on the scientific advisory board for Fibrogen and serves as a consultant for Google Ventures and Cell Signaling Technologies. C.K. and A.M.V. hold patents in the field of mSWI/SNF complex targeting therapeutics. S.A.S.V. is a member of the scientific advisory board at Ambry Genetics, for which no compensation is received. The other authors declare no competing interests.